Close

We use cookies to improve your experience of our website. Privacy Policy

Skip to main content
Menu

Dr Neil Dufton

Neil Dufton

Lecturer in Inflammatory Sciences

The William Harvey Research Institute
School of Medicine & Dentistry, Queen Mary University of London

Research

Interests

I am interested in developing an in vitro platform to understand the dynamic changes that occur during endothelial-to-mesenchymal transition (EndMT) and its role in regulating the tissue micro-environment. EndMT, which plays a central role in driving vascular dysfunction, is involved in the pathogenesis of numerous chronic diseases including liver fibrosis, atherosclerosis and rheumatoid arthritis. I would like develop an imaging platform that will allow me understand key stages of endothelial transition and the plasticity of the mesenchymal-derived cells to determine if EndMT can be used as a therapeutic target to reverse vascular dysfunction.

Publications of specific relevance to Predictive in vitro Models

Publications

2020

Dufton NP, Peghaire CR, Osuna-Almagro L, Raimondi C, Kalna V, Chauhan A, Webb G, Yang Y, Birdsey GM, Lalor P, Mason JC, Adams DH and Randi AM (2020). Author Correction: Dynamic regulation of canonical TGFβ signalling by endothelial transcription factor ERG protects from liver fibrogenesis (Nature Communications, (2017), 8, 1, (895), 10.1038/s41467-017-01169-0). Nature Communications  vol. 11, (1) 10.1038/s41467-020-15151-w

2019

Peghaire C, Dufton NP, Lang M, Salles-Crawley II, Ahnström J, Kalna V, Raimondi C, Pericleous C, Inuabasi L, Kiseleva R, Muzykantov VR, Mason JC, Birdsey GM and Randi AM (2019). The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature. Nature Communications  vol. 10, (1) 10.1038/s41467-019-12897-w

2018

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP and Fendt SM (2018). Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis  vol. 21, (3) 425-532. 10.1007/s10456-018-9613-x
Perbellini F, Watson SA, Scigliano M, Alayoubi S, Tkach S, Bardi I, Quaife N, Kane C, Dufton NP, Simon A, Sikkel MB, Faggian G, Randi AM, Gorelik J, Harding SE and Terracciano CM (2018). Investigation of cardiac fibroblasts using myocardial slices. Cardiovascular Research  vol. 114, (1) 77-89. 10.1093/cvr/cvx152

2017

Dufton NP, Peghaire CR, Osuna-Almagro L, Raimondi C, Kalna V, Chuahan A, Webb G, Yang Y, Birdsey GM, Lalor P, Mason JC, Adams DH and Randi AM (2017). Dynamic regulation of canonical TGFβ signalling by endothelial transcription factor ERG protects from liver fibrogenesis. Nature Communications  vol. 8, (1) 10.1038/s41467-017-01169-0
Shah AV, Birdsey GM, Peghaire C, Pitulescu ME, Dufton NP, Yang Y, Weinberg I, Osuna Almagro L, Payne L, Mason JC, Gerhardt H, Adams RH and Randi AM (2017). The endothelial transcription factor ERG mediates Angiopoietin-1-dependent control of Notch signalling and vascular stability. Nature Communications  vol. 8, 10.1038/ncomms16002

2016

Beuerle MG, Dufton NP, Randi AM and Gould IR (2016). Molecular dynamics studies on the DNA-binding process of ERG. Molecular Biosystems  vol. 12, (12) 3600-3610. 10.1039/c6mb00506c

2015

Birdsey GM, Shah AV, Dufton N, Reynolds LE, Almagro LO, Yang Y, Aspalter IM, Khan ST, Mason JC, Dejana E, Göttgens B, Hodivala-Dilke K, Gerhardt H, Adams RH and Randi AM (2015). The endothelial transcription factor erg promotes vascular stability and growth through Wnt/β-catenin signaling. Developmental Cell  vol. 32, (1) 82-96. 10.1016/j.devcel.2014.11.016

2012

Vong L, Ferraz JGP, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M and Wallace JL (2012). Up-Regulation of Annexin-A1 and Lipoxin A(4) in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis. Plos One  vol. 7, (6) 10.1371/journal.pone.0039244

2011

(2011). Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental in-flammation (The Journal of Immunology (2010) 184, (2611-2619)). Journal of Immunology  vol. 186, (4) 2684-2685. 10.4049/jimmunol.1090139

2010

Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M and Godson C (2010). FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. Faseb J  vol. 24, (11) 4240-4249. 10.1096/fj.10-159913
Dufton N and Perretti M (2010). Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther  vol. 127, (2) 175-188. 10.1016/j.pharmthera.2010.04.010
Yazid S, Ayoub SS, Solito E, McArthur S, Vo P, Dufton N and Flower RJ (2010). Anti-allergic drugs and the Annexin-A1 system. Pharmacol Rep  vol. 62, (3) 511-517. 10.1016/s1734-1140(10)70307-8
(2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol  vol. 184, (5) 2611-2619. 10.4049/jimmunol.0903526

2009

(2009). Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol  vol. 77, (5) 878-887. 10.1016/j.bcp.2008.11.011
Dufton NP, Hannon R, Perretti M and Flower R (2009). Quantitative Analysis of Promoter Activity by Green Fluorescent Protein (GFP) Target/Reporter Strategy in a Novel Transgenic alx/fpr-rs2 Null Mouse. Inflammation Research  vol. 58, (2) S252-S255. 10.1007/BF03354231